RSS   Newsletter   Contact   Advertise with us

Compugen appoints Michal Preminger as director

Staff Writer | Holon, Israel | May 26, 2017
CompugenMay 26, 2017, Holon, Israel - Compugen, a predictive drug discovery company, announced that Michal Preminger, executive director at Harvard University Office of Technology Development's Harvard Medical School site, has been appointed a director.
Prior to joining Harvard in 2005, Dr. Preminger held a number of senior executive business development and R&D positions in technology and biotechnology companies, including at Compugen, where she was a member of the management team that took the Company public in August 2000.

Dr. Preminger is a member of the board of directors of BioArray Genetics and Israel Brain Technologies, and a member of the Scientific Advisory Board at FutuRx (a partnership between Takeda Pharmaceuticals, Johnson & Johnson and Orbimed Ventures) and Prize4Life.

Dr. Preminger holds an undergraduate degree in Medicine from the Hebrew University of Jerusalem's School of Medicine, MSc and PhD from the Weizmann Institute of Science, and an MBA from INSEAD in Fontainebleau, France.